PNH arises from a non-inherited somatic mutation occurring in one or more hematopoietic stem cells following birth, resulting in clonal expansion of the abnormal cell population. No inherited gene variants are documented in the available packet, and no familial inheritance pattern is associated with PNH. The condition is classified as an acquired clonal disorder rather than a heritable genetic disease.

Structured diagnostic criteria and methods are not specified in the available packet data for PNH. Clinical recognition rests on identification of the characteristic combination of hemolytic anemia, bone marrow failure, and thrombotic events described in the disease definition. Detailed diagnostic workup protocols are not provided in the current packet.

Multiple FDA-approved complement-targeted therapies are available for PNH. Eculizumab is available under the brand name SOLIRIS and in biosimilar formulations BKEMV and EPYSQLI. Ravulizumab (ULTOMIRIS), a longer-acting complement C5 inhibitor, also carries active FDA approval. Additional approved agents include crovalimab (PIASKY), pegcetacoplan (EMPAVELI), iptacopan (FABHALTA), and danicopan (VOYDEYA). All listed agents carry active FDA approval status at the time of this report and represent distinct mechanisms across the complement cascade.

Longitudinal natural history data and long-term outcome information are not available in the current knowledge packet for PNH. No specific survival or life expectancy figures are provided in the packet data.

Numerous active clinical trial records are documented for PNH, including Phase 2 and Phase 3 investigations. Active studies include evaluations of iptacopan (FABHALTA) in long-term safety trials, combination therapy with pozelimab and cemdisiran, and additional complement pathway inhibitor approaches. The breadth of ongoing investigation reflects the active research landscape in complement-mediated rare hematologic disease.